Table 2.
Response endpoints for the entire cohort (N = 70).
| Efficacy endpoint | N (%) | 95% CI (%) |
|---|---|---|
| tpCR(ypT0/is,ypN0) | 39 (55.7) | 43.3–67.6 |
| bpCR(ypT0/is) | 41 (58.6) | 46.2–70.2 |
| Miller–Payne (MP) grades | ||
| MP score 2 | 9 (12.9) | 6.1–23.0 |
| MP score 3 | 12 (17.1) | 9.1–28.0 |
| MP score 4 | 8 (11.4) | 5.1–21.3 |
| MP score 5 | 41 (58.6) | 46.2–70.2 |
| Residual cancer burden (RCB) class | ||
| RCB class 0–I | 46 (65.7) | 53.4–76.7 |
| RCB class II | 20 (28.6) | 18.4–40.6 |
| RCB class III | 4 (5.7) | 1.6–14.0 |
| Objective response by MRI | 65 (92.9) | 84.1–97.6 |
| Complete response | 13 (18.6) | 10.3–29.7 |
| Partial response | 52 (74.3) | 62.4–84.0 |
| Complete or partial response | 65 (92.9) | 84.1–97.6 |
| Stable disease | 3 (4.3) | 0.9–12.0 |
| Progression disease | 2 (2.9) | 0.3–9.9 |
| Breast conserving surgery | 18 (25.7) | 16.3–37.8 |
Abbreviations: tpCR, total pathological complete response; bpCR, breast pathological complete response; CI, confidence interval; MRI: Magnetic resonance imaging.